Allan Farley could lose his sight if he is not treated with the Lucentis drug.
An NHS trust has pledged to review its decision to refuse a father-of-two treatment which consultants said could save his sight.
Allan Farley, 46, from Telford, suffers from a degenerative eye condition but had been denied the Lucentis drug by Telford and Wrekin Primary Care Trust.
A two-year course of injections can cost the NHS up to £18,000.
The trust said a treatment panel would look at the decision on 28 April following new evidence.
The injections have been available on the NHS as a treatment for other conditions since last April.
A spokesman for the trust said: "At the time of Mr Farley's initial review, there was no evidence that the treatment being sought would be effective in treating his condition.
"Since these hearings, the Royal College of Ophthalmologists has brought to our attention new case study evidence.
"This evidence will be reviewed at the trust's individual and specialist treatments panel."
Mr Farley, who suffers from punctate inner choroidopathy, which can lead to blindness, has called for the drug to be made available to all patients and was due to present his case before Parliament.
He said: "We want a standard process for all the PCTs up and down the country, because we are aware that people have received funding for this who are of a similar age to me and with a similar condition."